Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y
COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.
Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings
On Wednesday, Cencora, Inc.'s COR fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion.
Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q4 2024 Earnings Call Transcript November 6, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR Bob Mauch - President and CEO Laz Krikorian - SVP and CAO Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank Eric Percher - Nephron Research Stephanie Davis - Barclays Kevin Caliendo - UBS Eric Coldwell - Baird Erin Wright - Morgan Stanley Allen Lutz - Bank of America Charles Rhyee - TD Cowen Operator Hello, everyone, and welcome to today's Cencora Q4 Full Year 2024 Earnings Call. My name is Drew, and I'll be the operator today.
Here's Why Cencora (COR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cencora (COR) Tops Q4 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.21 per share. This compares to earnings of $2.86 per share a year ago.
Cencora to buy Retina Consultants of America for $4.6 bln
Drug distributor Cencora said on Wednesday it would acquire Retina Consultants of America (RCA) for $4.6 billion in cash, gaining access to its network of eye specialists.
Cencora to Report Q4 Earnings: What's in Store for the Stock?
COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
Cencora (COR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
